Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 63739-178

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 63739-178). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mckesson Corporation Dba Sky Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Packaging label for Clopidogrel Tablets, USP 300 mg film-coated tablets. The label, distributed by McKesson Corporation dba SKY Packaging, shows a carton containing 30 tablets (5 x 6 unit-dose). It includes usage instructions, storage conditions, and manufacturing information by Dr. Reddy's Laboratories Limited, India. The label features a dosage strength of 300 mg and includes a QR code for the Medication Guide.*

FDA Label Image

Figure1 (Figure1)

A horizontal bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of Clopidogrel bisulfate. Four PPIs are listed with dosages: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. Each bar represents the mean and 90% confidence interval of the effect on active metabolite AUC, with values ranging approximately from 0.4 to 1.4 on the x-axis.*

FDA Label Image

Figure2 (Figure2)

A line graph showing cumulative event rates over 12 months of follow-up comparing Clopidogrel (+ aspirin) with Placebo (+ aspirin). The x-axis represents months of follow-up, and the y-axis shows the cumulative event rate in percentage. The graph includes a p-value indicating statistical significance.*

FDA Label Image

Figure3 (Figure3)

This image is a forest plot chart depicting hazard ratios with 95% confidence intervals for Clopidogrel bisulfate compared to placebo across various subgroups. Subgroups include age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, use of Heparin/LMWH, aspirin dosage, GP IIb/IIIa antagonist, beta-blocker, and ACE inhibitor. The chart presents the number of subjects, event occurrences (n and %), and visually compares the effect of Clopidogrel bisulfate versus placebo within each subgroup and overall.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve graph depicting the percentage of deaths before first discharge over days since randomization up to 28 days. The graph compares Clopidogrel bisulfate and placebo groups, showing the number of deaths and a proportional risk reduction statistic.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier curve chart comparing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization between placebo and clopidogrel groups. The chart shows the proportion of events with clopidogrel demonstrating a 9% proportional risk reduction compared to placebo, with event rates of 9.2% and 10.1%, respectively.*

FDA Label Image

Figure6 (Figure6)

A forest plot displaying odds ratios with 99% confidence intervals comparing Clopidogrel bisulfate versus placebo across various subgroups such as gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent administration. The plot shows individual subgroup results and an overall odds ratio summary.*

FDA Label Image

Figure7 (Figure7)

A line graph depicting the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up. The graph compares two treatments: Clopidogrel and Aspirin, with Clopidogrel showing a slightly lower event rate than Aspirin. The p-value for the comparison is 0.045.*

FDA Label Image

Figure8 (Figure8)

A forest plot chart showing hazard ratios with 95% confidence intervals for three qualifying conditions: Stroke, MI, and PAD, along with an Overall category. The plot compares outcomes favoring Clopidogrel versus Aspirin based on the given data counts and percentages for Clopidogrel and Aspirin groups.*

FDA Label Image

Structure (Structure)

Chemical structure of Clopidogrel bisulfate showing its molecular arrangement including a bicyclic ring system with sulfur, a chlorophenyl group, and associated functional groups, along with the bisulfate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.